- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07489651
RE104 Sikkerheds- og Effektivitetsundersøgelse ved Generaliseret Angstlidelse
En randomiseret, dobbeltblind, placebokontrolleret undersøgelse, der evaluerer sikkerheden og effekten af RE104 til injektion i behandlingen af generaliseret angstlidelse
The purpose of this study is to determine if treatment with a single and/or repeat dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Mark Pollack Chief Medical Officer, M.D.
- Telefonnummer: 1-888-880-REUN
- E-mail: info@reunionneuro.com
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35209
- Rekruttering
- University of Alabama (UAB) Clinical Research Unit (CRU)
-
Kontakt:
- Seher Premani
- Telefonnummer: spremani@uab.edu
- E-mail: spremani@uab.edu
-
-
Arizona
-
Gilbert, Arizona, Forenede Stater, 85234
- Rekruttering
- Lighthouse Psychiatry
-
Kontakt:
- Matt Longson
- Telefonnummer: 435-268-5800
- E-mail: Contact@neosciclinicalresearch.com
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72211
- Rekruttering
- Preferred Research Partners, Inc.
-
Kontakt:
- Stacy Tierney
- Telefonnummer: 111 501-553-9987
- E-mail: stierney@preferredresearchpartners.com
-
-
California
-
Garden Grove, California, Forenede Stater, 92845
- Rekruttering
- Collaborative Neuroscience Research, LLC
-
Kontakt:
- CNS Outreach Department
- Telefonnummer: 844-424-9494
- E-mail: cns.outreach@cenexel.com
-
La Jolla, California, Forenede Stater, 92037
- Rekruttering
- Kadima Neuropsychiatry Institute
-
Kontakt:
- Angelica Lu
- Telefonnummer: 858-775-2053
- E-mail: angelical@kadimanp.com
-
San Francisco, California, Forenede Stater, 94114
- Rekruttering
- Open Mind Therapeutics
-
Kontakt:
- Victoria Vega
- Telefonnummer: 415-906-7399
- E-mail: victoria@openmindcollective.org
-
Santa Monica, California, Forenede Stater, 90404
- Rekruttering
- TRIP Clinic at Psychedelic Science Institute
-
Kontakt:
- Ashley Ramos
- E-mail: trialadmin@psychedlicsci.com
-
-
Florida
-
Lauderhill, Florida, Forenede Stater, 33319
- Rekruttering
- Innovative Clinical Research, Inc.
-
Kontakt:
- Melissa Rodco
- Telefonnummer: 305-722-8444
- E-mail: mrodco@segaltrials.com
-
Tampa, Florida, Forenede Stater, 33613
- Rekruttering
- University of South Florida
-
Kontakt:
- Genesis Estramera
- Telefonnummer: 813-974-1404
- E-mail: gestramera@usf.edu
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30331
- Rekruttering
- Atlanta Center for Medical Research
-
Kontakt:
- Amber Tannahill
- Telefonnummer: 404-881-5800
- E-mail: a.tannahill@cenexel.com
-
Decatur, Georgia, Forenede Stater, 30030
- Rekruttering
- CenExel iResearch, LLC
-
Kontakt:
- Michael Mahaffrey
- E-mail: m.mahaffrey@cenexel.com
-
Norcross, Georgia, Forenede Stater, 30092
- Rekruttering
- Evergreen Clinical Trials
-
Kontakt:
- Stephen Wheeler
- Telefonnummer: 943-230-1385
- E-mail: stephen@evergreenstrials.com
-
Savannah, Georgia, Forenede Stater, 31405
- Rekruttering
- CenExel iResearch, LLC
-
Kontakt:
- Michelle Lagares
- Telefonnummer: 912-744-0800
- E-mail: M.Lagares@CenExel.com
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60640
- Rekruttering
- Uptown Research Institute
-
Kontakt:
- Deborah Jones-Miller
- Telefonnummer: 117 773-989-8313
- E-mail: Djones-miller@uptownresearch.com
-
-
Michigan
-
Novi, Michigan, Forenede Stater, 48377
- Rekruttering
- Henry Ford Medical Center - Columbus
-
Kontakt:
- Madeline Bross
- Telefonnummer: 248-344-7366
- E-mail: mbross1@hfhs.org
-
-
Missouri
-
Saint Charles, Missouri, Forenede Stater, 63304
- Rekruttering
- Midwest Research Group
-
Kontakt:
- Lindsay vanWinkle
- Telefonnummer: 3 636-946-8032
- E-mail: lvanwinkle@midwestresearchgroup.com
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 14624
- Rekruttering
- UNM Research Program Psychedelic Therapies
-
Kontakt:
- Hector Garcia
- Telefonnummer: 505-675-0582
- E-mail: hecgarcia@salud.unm.edu
-
-
New York
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- NYU-H+C Clinical and Translational Science Institute
-
Kontakt:
- Jillian Kelly
- Telefonnummer: 212-404-7764
- E-mail: Jillian.kelly@nyulangone.org
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- Rekruttering
- University of North Carolina at Chapel Hill
-
Kontakt:
- Julia Hoffman
- E-mail: julia_hoffmann1@med.unc.edu
-
-
Ohio
-
North Canton, Ohio, Forenede Stater, 44720
- Rekruttering
- Neuro-Behavioral Clinical Research, Inc.
-
Kontakt:
- Crystal Blackford
- Telefonnummer: 330-493-1118
- E-mail: cblackford@nb-cr.com
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97210
- Rekruttering
- Summit Headlands LLC
-
Kontakt:
- Tyler Leecing
- E-mail: tyler.leecing@summitnetwork.com
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- University of Pennsylvania
-
Kontakt:
- Erin Blase
- Telefonnummer: 215-746-6419
- E-mail: erin.blase@pennmedicine.upenn.edu
-
West Chester, Pennsylvania, Forenede Stater, 19380
- Trukket tilbage
- Suburban Research Associates
-
-
Texas
-
Austin, Texas, Forenede Stater, 78737
- Rekruttering
- Austin Clinical Trial Partners
-
Kontakt:
- Kara Chilek
- Telefonnummer: 512-521-0595
- E-mail: studyinfo@austinCTP.com
-
Austin, Texas, Forenede Stater, 78759
- Rekruttering
- BioBehavioral Research Austion
-
Kontakt:
- Tracie Wesson
- Telefonnummer: 402-934-0044
- E-mail: tracie.wesson@qcrnetwork.com
-
Plano, Texas, Forenede Stater, 75093
- Rekruttering
- Aim Trials, LLC
-
Kontakt:
- Sonia Prashar
- Telefonnummer: 214-856-2778
- E-mail: sonia.prashar@aimtrials.com
-
-
Utah
-
Draper, Utah, Forenede Stater, 84020
- Rekruttering
- Cedar Clinical Research
-
Kontakt:
- Jane Bjorklund
- Telefonnummer: 801-369-4219
- E-mail: jane.bjorklund@numinusnetwork.com
-
Orem, Utah, Forenede Stater, 84058
- Rekruttering
- Inner Space State Street
-
Kontakt:
- Janet Jimenez
- Telefonnummer: 801-871-5516
- E-mail: apply@innerspaceresearch.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Has Generalized Anxiety Disorder as defined by DSM-5-TR
- If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant.
- Is willing and able to comply with the conditions and requirements of the study
Exclusion Criteria:
- Has a significant risk of suicide
- Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
- Has other concurrent psychiatric disorders that is the primary disorder.
- Has other medically significant conditions rendering unsuitability for the study
- Has used or will need to use prohibited medications or therapies
- Has a known sensitivity or intolerance to study intervention or potential rescue medications
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
A single subcutaneous injection of 0.9% sodium chloride for injection per dosing session |
Single-dose (Part A) or Repeat-dose (Part B), subcutaneous injection(s) of 0.9% sodium chloride for injection |
|
Eksperimentel: 30 mg RE104
A single subcutaneous injection of 30 mg RE104 for Injection per dosing session |
Single dose (Part A) or Repeat-dose (Part B), subcutaneous injection(s) of RE104 for Injection |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
RE104 when administered as a single 30 mg dose or as two 30 mg doses 3 weeks apart versus placebo change from Baseline at Week 4 in Hamilton Anxiety Rating Scale (HAM-A) total score
Tidsramme: Week 4
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Week 4
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
RE104 versus placebo changes in total score from baseline in Hamilton Anxiety Rating Scale (HAM-A)
Tidsramme: Weeks 1, 2, 8 and 12
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Weeks 1, 2, 8 and 12
|
|
RE104 versus placebo percentage of participants with HAM-A response (≥50% reduction in score from Baseline)
Tidsramme: Weeks 1, 2, 4, 8 and 12
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Weeks 1, 2, 4, 8 and 12
|
|
RE104 versus placebo percentage of participants with HAM-A remission (total score ≤7)
Tidsramme: Day 1 and Weeks 1, 2, 4, 8 and 12
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Day 1 and Weeks 1, 2, 4, 8 and 12
|
|
RE104 versus placebo change from Baseline at Weeks 1, 2, 4, 8, and 12 in Hospital Anxiety and Depression Scale (HADS) depression subscore
Tidsramme: Weeks 1, 2, 4, 8 and 12
|
The Hospital Anxiety and Depression Scale (HADS) is a self-reported scale measure the severity of depression and anxiety in patients with comorbid medical conditions. The scale consists of 14 items (7 for anxiety and 7 for depression), with a score ranging between 0 and 21 for the anxiety and depression subscales. |
Weeks 1, 2, 4, 8 and 12
|
|
RE104 versus placebo incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness.
Tidsramme: From dosing through study completion (post-dose follow-up is for 12 weeks)
|
A treatment-emergent adverse event (TEAE) is defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a study drug. |
From dosing through study completion (post-dose follow-up is for 12 weeks)
|
|
RE104 versus placebo change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) (Part B only)
Tidsramme: Weeks 1, 2, 4, 8, and 12
|
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression. |
Weeks 1, 2, 4, 8, and 12
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Mark Pollack, M.D., Reunion Neuroscience Inc
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- RE104-203-GAD
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .